Therapeutic effects of candesartan in inflammatory skin disorders by suppressing Th17 differentiation
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110995 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von So-Eun Son und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Psoriasis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Research Foundation of Korea, Ministry of Science, ICT and Future Planning.
Abstract (Originalsprache)
As angiotensin II is associated with inflammation, type I angiotensin II receptor blockers (ARBs) exibit anti-inflammatory effects in patients with hypertension as well as inflammatory disease animal models including arthritis models. The present study aimed to investigate whether ARBs exert anti-inflammatory effects in vivo in skin disorders. We tested effects of ARBs on 1-chloro-2,4-dinitrobenzene(CDNB)-induced atopic dermatitis-like and imiquimod-induced psoriasis-like skin models. CDNB-induced atopic dermatitis-like skin lesions were suppressed by administration of candesartan or telmisartan. The suppressive effect of telmisartan was blocked by the presence of GW9662, a selective PPARγ inhibitor, but not that of candesartan. Both ARBs suppressed increases in pro-inflammatory cytokine (IL-4, IL-13, IFN-γ, and IL-17A) levels, and GW9662 inhibited telmisartan-induced suppression but not candesartan. Candesartan significantly inhibited in vitro differentiation of naïve T cells into Th17 cells to a greater extent than telmisartan. In the imiquimod-induced psoriasis model, whose primary etiology is activation of IL-23/IL-17 axis, candesartan significantly suppressed psoriasis-like skin lesions and Th17 cell populations in both lymph nodes and spleens to a greater extent than telmisartan. Overall, certain ARBs may have anti-inflammatory effects in skin diseases. Candesartan may have therapeutic implications in inflammatory skin disorders by suppressing Th17 differentiation, while telmisartan might have therapeutic potential by activating PPARγ.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.
- Department of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea; Department of Fundamental Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seou…
Förderung
- National Research Foundation of Korea
- Ministry of Science, ICT and Future Planning
Zitieren
APA
Son, S. E., & Im, D. S. (2023). Therapeutic effects of candesartan in inflammatory skin disorders by suppressing Th17 differentiation. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110995
Vancouver
Son SE, Im DS. Therapeutic effects of candesartan in inflammatory skin disorders by suppressing Th17 differentiation. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110995
BibTeX
@article{Son2023,
author = {Son, So-Eun and Im, Dong-Soon},
title = {Therapeutic effects of candesartan in inflammatory skin disorders by suppressing Th17 differentiation},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110995}
}
EUVIMED